TQB3205 / Sino Biopharm - LARVOL DELTA

TQB3205-I-01: Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=156 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Sino Biopharmaceutical Limited…announces that TQB3205 'Pan-KRAS inhibitor'…has received the approval for investigational new drug (IND) application from the United States Food and Drug Administration (FDA) for the treatment of advanced malignant tumors (HKEXnews)

IND • Solid Tumor

Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=156 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Sino Biopharmaceutical Limited…announces that TQB3205 ’pan-KRAS inhibitor’, a national Category 1 innovative drug independently developed by Chia Tai Tianqing Pharmaceutical Group,…has received the clinical trial approval from China’s National Medical Products Administration (NMPA) for the intended treatment of advanced malignant tumors (HKEXnews)

New trial • Solid Tumor